| Abstrakt: |
Keywords: Breast Cancer; Cancer; Drugs and Therapies; Health and Medicine; Immunotherapy; Oncology; Women's Health EN Breast Cancer Cancer Drugs and Therapies Health and Medicine Immunotherapy Oncology Women's Health 108 108 1 07/03/23 20230704 NES 230704 2023 JUL 4 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on breast cancer. Although, recent reports support the presence of tumor infiltrating lymphocytes (TILs) in breast cancer that make it favorable for PD-1/PD-L1 mediated immunotherapy, which is effective in PD-L1 positive patients. Recently, anti-PD-1 (pembrolizumab) and anti-PD-L1 (atezolizumab) gets FDA approval for breast cancer treatment and make PD-1/PD-L1 immunotherapy is meaningful for further research.". [Extracted from the article] |
